argenx SE (ARGX) Q1 2022 Earnings Call Transcript

Prepared Remarks

Questions and Answers

Call Participants

Prepared Remarks:

Operator

Good morning. My name is Adil, and I will be your conference operator today. At this time, I would like to welcome everyone to today's call. [Operator instructions]. Thank you.

I'd like to introduce Beth DelGiacco, Vice President of Corporate Communications and Investor Relations. You may now begin your conference

Beth DelGiacco

Thank you, operator. Two press releases were issued earlier today, one which summarizes the positive results from our Phase 3 ADVANCE trial and the other which outlines our first quarter 2022 financial results and business updates. These can be found on our website along with the presentation for today's webcast.

Before we begin, I'd like to remind you on Slide 2 that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical developments, regulatory timelines, the potential success of our product candidates, financial projections, and upcoming milestones. Actual results may differ materially from those indicated by these statements. argenx is not under any obligation to update statements regarding the future or to conform those statements in relation to actual results unless required by law. I'm joined on the call today by Tim Van Hauwermeiren, Chief Executive Officer; Luc Truyen, Chief Medical Officer; Karl Gubitz, Chief Financial Officer; and Keith Woods, Chief Operating Officer.

I will now turn the call over to Tim.

Tim Van Hauwermeiren

Thank you, Beth. Good morning, everyone, and thank you for joining today's call.

Slide 3. I'm thrilled to discuss our strong first quarter results, in particular, we have shared two sets of exciting news this morning. First, we have exceeded expectations for the first quarter of our U.S. VYVGART launch, generating $21.2 million in net product revenues. Keith is going to provide more context on our commercial progress later in the call, but at a high level, this demonstrates both the clear unmet need for new treatments in the GMT community and the tremendous execution of our team to translate their needs into new demands from patients and physicians.

Our carefully crafted strategies with regards to pay physicians and patients on paying off today, and I'm more confident than ever that we have the right team in place to bring VYVGART to the GMG community. We're also on track to launch in Japan this month. So we are advancing well on our global launch strategy. Second, we announced positive results from the ADVANCE trial, the first of our two registrational ITP trials. We met a very high bar in achieving these positive results with a difficult primary endpoint and a refractory very heavily pretreated patient group. We also have a robust set of data from secondary endpoints that provide additional context on patent conductivity throughout the study. These data points align closely with how physicians treat ITP patients and will be critical as we look to bring the new treatment option to the ITP community. ITP is now the second serious autoimmune disease in which we've shown a statistically significant treatment benefit. We're starting to see the reality of efgartigimod as a pipeline in a product.